Insights

Innovative Therapeutics Palatin Technologies has a strong pipeline of first-in-class melanocortin-based therapeutics, including the FDA-approved Vyleesi for hypoactive sexual desire disorder and promising treatments for ocular and inflammatory conditions, presenting significant opportunities to engage healthcare providers and institutions focused on women's health, ophthalmology, and inflammation-related diseases.

Strategic Collaborations Recent partnerships with global pharmaceutical companies like Boehringer Ingelheim highlight Palatin’s active engagement in joint research and development efforts, creating avenues for co-marketing, licensing, and expanding market reach into retinal and inflammatory disease segments.

Expanding Market Focus With ongoing clinical trials targeting dry eye disease, uveitis, retinopathies, and inflammatory conditions such as ulcerative colitis and kidney disease, Palatin is positioning itself to penetrate diverse therapeutic areas, offering sales teams multiple entry points in specialists’ markets.

Financial Growth Potential Palatin’s recent progress in advancing its clinical candidates, combined with a revenue range of 10 to 50 million dollars and focused R&D investments, indicates potential growth opportunities for investors and partners aligned with innovative biotech breakthroughs.

Market Differentiation As the first company to secure FDA approval for a melanocortin-based therapy, Palatin stands out in the biotech space, making it an attractive partner for organizations seeking novel treatment solutions and early adoption opportunities in a competitive pharmaceutical landscape.

Palatin Technologies Tech Stack

Palatin Technologies uses 8 technology products and services including Twitter Ads, Chosen, JSON-LD, and more. Explore Palatin Technologies's tech stack below.

  • Twitter Ads
    Advertising
  • Chosen
    Javascript Frameworks
  • JSON-LD
    Javascript Frameworks
  • Modernizr
    Javascript Libraries
  • Google Maps
    Maps
  • Elementor
    Page Builders
  • WP Engine
    Platform As A Service
  • Cloudflare Bot Management
    Security

Media & News

Palatin Technologies's Email Address Formats

Palatin Technologies uses at least 1 format(s):
Palatin Technologies Email FormatsExamplePercentage
FLast@palatin.comJDoe@palatin.com
49%
Last@palatin.comDoe@palatin.com
1%
FLast@palatin.comJDoe@palatin.com
49%
Last@palatin.comDoe@palatin.com
1%

Frequently Asked Questions

Where is Palatin Technologies's headquarters located?

Minus sign iconPlus sign icon
Palatin Technologies's main headquarters is located at US. The company has employees across 2 continents, including North AmericaAsia.

What is Palatin Technologies's phone number?

Minus sign iconPlus sign icon
You can contact Palatin Technologies's main corporate office by phone at . For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is Palatin Technologies's stock symbol?

Minus sign iconPlus sign icon
Palatin Technologies is a publicly traded company; the company's stock symbol is PTN.

What is Palatin Technologies's official website and social media links?

Minus sign iconPlus sign icon
Palatin Technologies's official website is palatin.com and has social profiles on LinkedInCrunchbase.

How much revenue does Palatin Technologies generate?

Minus sign iconPlus sign icon
As of October 2025, Palatin Technologies's annual revenue is estimated to be $13M.

What is Palatin Technologies's SIC code NAICS code?

Minus sign iconPlus sign icon
Palatin Technologies's SIC code is 2869 - Industrial Organic Chemicals, Not Elsewhere Classified NAICS code is 3254 - Pharmaceutical and Medicine Manufacturing.

How many employees does Palatin Technologies have currently?

Minus sign iconPlus sign icon
As of October 2025, Palatin Technologies has approximately 51 employees across 2 continents, including North AmericaAsia. Key team members include Chief Medical Officer: M. R.Chief Legal Officer: S. S.Vice President Of Research: J. D.. Explore Palatin Technologies's employee directory with LeadIQ.

What industry does Palatin Technologies belong to?

Minus sign iconPlus sign icon
Palatin Technologies operates in the Pharmaceutical Manufacturing industry.

What technology does Palatin Technologies use?

Minus sign iconPlus sign icon
Palatin Technologies's tech stack includes Twitter AdsChosenJSON-LDModernizrGoogle MapsElementorWP EngineCloudflare Bot Management.

What is Palatin Technologies's email format?

Minus sign iconPlus sign icon
Palatin Technologies's email format typically follows the pattern of FLast@palatin.com. Find more Palatin Technologies email formats with LeadIQ.

How much funding has Palatin Technologies raised to date?

Minus sign iconPlus sign icon
As of October 2025, Palatin Technologies has raised $1.1M in funding. The last funding round occurred on May 07, 2025 for $1.1M.
Palatin Technologies

Palatin Technologies

Pharmaceutical ManufacturingUnited States51-200 Employees

Palatin (NYSE American: PTN) is a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin peptide receptor system. The melanocortin system is involved in regulating important physiological activities such as food intake and energy balance, desire and arousal, and the resolution of harmful inflammation. We are the first company to obtain FDA approval for a melanocortin based therapeutic, Vyleesi®, a treatment for women with hypoactive sexual desire disorder (HSDD).

With the successful development of Vyleesi® and our extensive experience in the development of melanocortin based therapeutics, we are now focused on developing therapeutics that take advantage of the key role that the melanocortin system plays in the resolution of harmful inflammation. This has the potential to treat diseases that affect the eye, gastrointestinal system and the kidney. 

Our most advanced ocular product is PL9643, a topical treatment for dry eye disease, which is targeted to enter Phase 3 clinical trials in 2H 2021. We also have therapeutics in earlier stages of development for ophthalmic indications such as non-infectious uveitis, retinopathies and corneal diseases.

Therapeutics that modulate the activity of the melanocortin system will have broad utility and to establish this, we are planning to conduct proof of concept clinical studies in ulcerative colitis and kidney disease.  

Vyleesi® is the first and only on-demand, FDA-approved treatment for premenopausal women  suffering with HSDD, which affects 1 in 10 pre-menopausal women. Learn about this condition here: https://www.unblush.com/ 

To learn more about Vyleesi®, including Important Safety Information, visit here: https://www.vyleesi.com/ 

We are very excited by the tremendous potential our therapeutics have to positively impact the lives of patients and the value we can build for our shareholders. Find more information about our programs: www.palatin.com

Section iconCompany Overview

Headquarters
US
Phone number
SIC Code
2869 - Industrial Organic Chemicals, Not Elsewhere Classified
Stock Symbol
PTN
NAICS Code
3254 - Pharmaceutical and Medicine Manufacturing
Employees
51-200

Section iconFunding & Financials

  • $1.1M

    Palatin Technologies has raised a total of $1.1M of funding over 12 rounds. Their latest funding round was raised on May 07, 2025 in the amount of $1.1M.

  • $25M$50M

    Palatin Technologies's revenue is estimated to be in the range of $25M$50M

Section iconFunding & Financials

  • $1.1M

    Palatin Technologies has raised a total of $1.1M of funding over 12 rounds. Their latest funding round was raised on May 07, 2025 in the amount of $1.1M.

  • $25M$50M

    Palatin Technologies's revenue is estimated to be in the range of $25M$50M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.